---
title: 'Associate Director, Chemical Development at Nurix'
canonical: 'https://feeny.ai/job/associate-director-chemical-development-nurix-brisbane-california-879xrghm1rjq'
type: 'job'
last_seen: '2026-09-10'
---

# Associate Director, Chemical Development at Nurix

- **Company:** Nurix
- **Location:** Brisbane California, United States
- **Posted:** 2026-09-02
- **Last confirmed live:** 2026-09-10
- **Apply:** https://job-boards.greenhouse.io/nurix/jobs/8779770002

## Job description

## *DNP* *CBD*

Nurix Therapeutics, Inc. has job openings (multiple) for the position of Associate Director, Chemical Development based out of its location in Brisbane, CA. The offered wage is: $243,410.16 to $256,800 per year. The base salary for this position is $243,410.16, higher compensation may be available with advanced skills and/or experience.

Job Duties: Responsible for regulatory starting materials (RSMs) and Drug Substance (DS) cGMP manufacturing related activities, including scale-up of candidate compounds to support candidate selection during drug discovery, from preclinical development through commercialization. Identification, selection, and management of Contract Manufacturing Organizations (CMOs) for process optimization and cGMP manufacture of DS in support of ongoing clinical programs. Delivery of robust, scalable, and cost-effective phase-appropriate manufacturing of DS that meets or exceeds quality and regulatory requirements. Implement phase-appropriate process characterization, identify critical quality attributes, and implement controls, including selection and justification of regulatory starting materials (RSMs) to ensure that all CROs and CMOs are using systems and processes in compliance with all relevant regulatory standards and to ensure consistency of DS quality. Lead the characterization of late phase programs according to the principles of QbD (mapping studies, DOEs) to identify critical quality attributes and critical process parameters (including edge of failure and proven acceptable ranges) and implement DS Control Strategy to support NDAs/MAAs. Support management of RSMs and DS supply chain and logistics in support of demand for clinical studies and commercial products. Develop and execute plans for the primary stability registration and validation batches of DS as required by cGMP, ICH (International Conference of Harmonization) and FDA regulations. Lead process validation programs to support commercialization. Prepare and/or review CMC sections of INDs, CTAs, NDAs, MAAs and other regulatory submissions; represent the company as the DS expert before U.S. and European regulatory authorities. Prepare, review, or approve cGMP batch records, CMC regulatory and Quality documents. Prepare technical reports, publications, and oral presentations. Up to 50% domestic and foreign travel is required. Percentage of foreign and domestic travel can vary by project needs.

Requirements:  Doctorate (PhD) in Chemical Engineering, Pharmaceutical Chemistry, Organic Chemistry, Pharmaceutics, Pharmaceutical Science, or related scientific discipline plus 5 years of industry experience in a pharmaceutical or biotechnology CMC/cGMP environment and demonstrated experience with: Development of safe, scalable, phase-appropriate routes of synthesis to drug substance targets; Oversight of US and international contract manufacturing organizations for the manufacture of cGMP new chemical entity drug substances; Authoring Module 3 Sections for IND/IMPD and/or NDA/MAA filings; and ICH Q7, FDA 21 CFR Part 210, 211 and EU GMP Volume 4 Part I and II guidelines.

Send Resume To: HR@nurixtx.com, reference Position ID No NUR-028 in the email.

## About Nurix

## Company Overview
- **One-liner**: Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines to outmatch disease by harnessing the cell’s natural protein disposal system.
- **Entity Type**: Public (NASDAQ: NRIX)
- **Headquarters**: San Francisco, California, USA
- **Founded**: 2009
- **Founders**: Not publicly listed as individual founders; the company was spun out from research at UC Berkeley and UC San Francisco.

## Core Business
- **Primary industry**: Biopharmaceuticals / Targeted Protein Degradation
- **Target customers**: B2B (pharma partners) and B2C (patients via clinical trials and eventual commercial therapies); enterprise-level partnerships with major pharma.
- **Mission or purpose statement**: "Writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease." [nurixtx.com](https://www.nurixtx.com/)

## Products & Services
- **Bexobrutideg (NX-5948)**: A potential best-in-class BTK degrader in Phase 1b/2 clinical trials for relapsed/refractory CLL/SLL and chronic spontaneous urticaria. Co-developed and co-commercialized with Roche under a global collaboration announced June 2026. [nurixtx.com](https://www.nurixtx.com/)
- **NX-2127**: A BTK degrader in clinical development for B-cell malignancies.
- **CBL-B Inhibitor (NX-1607)**: An E3 ligase inhibitor designed to activate T cells for immuno-oncology, in Phase 1 clinical trials.
- **IRAK4 Degrader**: A partnered program with Gilead in Phase 1 for inflammatory diseases.
- **STAT6 Degrader**: A partnered program with Sanofi in IND-enabling studies.
- **DEL-AI Discovery Engine**: A proprietary, fully AI-integrated platform combining DNA-encoded libraries (DEL), automated chemistry, and machine learning to design and optimize targeted protein degraders and degrader-antibody conjugates (DACs).

## Market Standing
- **Valuation/Market Cap**: Not publicly available in the provided search results; as a public company (NRIX), market cap fluctuates daily. Check financial platforms for the latest figure.
- **Key Metric**: Annual Revenue (public) — Not publicly available in the provided search results; as a clinical-stage biotech, revenue is typically minimal or pre-revenue. Total funding raised prior to IPO is not detailed in the provided results.
- **Notable Investors/Partners**: Roche (global co-development and co-commercialization collaboration for bexobrutideg, announced June 2026), Gilead (partnered IRAK4 degrader program), Sanofi (partnered STAT6 degrader program).
- **Growth Signals**: Announced a landmark global collaboration with Roche in June 2026 to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. Presented positive Phase 1a/b data for bexobrutideg in CLL/SLL and chronic spontaneous urticaria in 2026. Multiple partnered and wholly owned pipeline programs advancing through clinical and preclinical stages.

## Competitive Advantages
- **Proprietary DEL-AI Discovery Engine**: A fully AI-integrated platform combining DNA-encoded libraries, automated chemistry, and machine learning to design degraders against any protein class, providing a significant speed and innovation advantage. [nurixtx.com](https://www.nurixtx.com/)
- **Unparalleled Ligase Expertise**: Deep understanding of E3 ligase biochemistry and biology, a critical and complex component of the protein degradation mechanism, giving them a unique moat.
- **Multi-Modal Pipeline**: Developing both small molecule degraders and Degrader-Antibody Conjugates (DACs), expanding the therapeutic reach and creating multiple shots on goal.
- **Strong Partnership Network**: Collaborations with top-tier pharma (Roche, Gilead, Sanofi) validate their platform and provide non-dilutive funding and shared risk.

## Strategic Focus
- **Clinical Advancement**: Driving lead asset bexobrutideg through pivotal trials in CLL/SLL and expanding into immunology (chronic spontaneous urticaria) and neurology.
- **Platform Expansion**: Leveraging the DEL-AI engine to develop Degrader-Antibody Conjugates (DACs) for enhanced cell specificity and safety.
- **Pipeline Breadth**: Advancing a multi-modal pipeline across oncology, immunology, and neurology, both wholly owned and through strategic partnerships.
- **Partnership Leverage**: Deepening collaborations with Roche, Gilead, and Sanofi to co-develop and co-commercialize programs, reducing risk and accelerating timelines.

## Why Work Here
- **Culture**: Mission-focused, values-based, and spirited culture emphasizing "breakthrough innovation," "leadership," "accountability," and "zealousness." Employees are encouraged to "think big and act bold." [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Work with Industry Leaders**: The team includes scientific innovators who built the protein degradation field, seasoned executives with biotech scaling expertise, and leading clinicians. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Growth & Impact**: Employees can "wear many hats" and gain broad exposure in a lean, virtual drug developer environment. The company emphasizes career growth and opportunity-rich experiences.
- **Work Policy**: Onsite in Brisbane, CA (San Francisco Bay Area) for most roles, as indicated by job postings. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
- **Benefits**: Comprehensive health and welfare plans, enhanced parental leave, wellness reimbursement, 401(k) employer match, and a highly collaborative culture. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Engineering/Science Culture**: Described as "mission-focused, values-based, and spirited," with a focus on "intellectual and technical ingenuity" and "intelligent risk-taking." The company is a "virtual drug developer" with a lean internal infrastructure, relying on SaaS and cloud platforms. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)

## Sources
1. [nurixtx.com](https://www.nurixtx.com/)
2. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
3. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
4. [nurixtx.com](https://www.nurixtx.com/our-story/)

## Other roles at Nurix

- [Associate Director, electronic Quality Management System (eQMS)](https://feeny.ai/job/associate-director-electronic-quality-management-system-eqms-nurix-brisbane-k35rdgj6th4k) — Brisbane, CA
- [Director, Nonclinical Toxicology Operations](https://feeny.ai/job/director-nonclinical-toxicology-operations-nurix-brisbane-california-a7ynjr847xvh) — Brisbane California, United States
- [Director, Medical Affairs - Immunology](https://feeny.ai/job/director-medical-affairs-immunology-nurix-brisbane-california-8q3w67dea5xq) — Brisbane California, United States
- [Senior Manager/Associate Director, Regulatory Affairs (Strategy, Hematology Oncology)](https://feeny.ai/job/senior-manager-associate-director-regulatory-affairs-strategy-hematology-zsgdf1qycbew) — Brisbane California, United States
- [Senior Administrative Assistant, R&ED](https://feeny.ai/job/senior-administrative-assistant-r-ed-nurix-brisbane-california-9k9rhmyvd955) — Brisbane California, United States
- [Senior Director, Quality Control](https://feeny.ai/job/senior-director-quality-control-nurix-brisbane-california-d4hqe06vb3t7) — Brisbane California, United States
- [Associate Director, Chemical Engineering](https://feeny.ai/job/associate-director-chemical-engineering-nurix-brisbane-california-6gbpc8ben8eh) — Brisbane California, United States
- [Senior Analyst, FP&A](https://feeny.ai/job/senior-analyst-fp-a-nurix-brisbane-california-g7qxkkvsfwbf) — Brisbane California, United States
- [Medical Director / Senior Medical Director](https://feeny.ai/job/medical-director-senior-medical-director-nurix-brisbane-california-wkgs5dx1e7eq) — Brisbane California, United States
- [Medical Director / Senior Medical Director](https://feeny.ai/job/medical-director-senior-medical-director-nurix-brisbane-california-57ydhjmqgfm6) — Brisbane California, United States